Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Kuros' IND for phase IIa trial of KUR-113 for spinal fusion

Sep. 3, 2019

ObsEva reports mechanism-of-action data on oxytocin receptor antagonist nolasiban

Sep. 3, 2019

Suven evaluates SUVN-G3031 in phase II trial for narcolepsy with and without cataplexy

Sep. 3, 2019

eXIthera Pharmaceuticals divulges coagulation factor XIa and kallikrein inhibitors

Sep. 3, 2019

Eli Lilly and Company describes PDE1 inhibitors

Sep. 3, 2019

Crinetics Pharmaceuticals identifies somatostatin SST5 receptor agonists

Sep. 3, 2019

TREM2 correlates with slow decline in AD

Sep. 3, 2019

Daiichi Sankyo presents new analgesics

Sep. 3, 2019

HIV rebound shows diverse sources, identical virus

Sep. 3, 2019

KBP Biosciences patents new bacterial LpxC inhibitors

Sep. 3, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...